A phase II, open-label, multi-center study to assess pharmacokinetics (PK), safety and efficacy of POL7080 co-administered with standard of care (SoC) treatment in patients with ventilator- associated pneumonia (VAP) due to suspected or documented Pseudomonas aeruginosa infection. - POL7080-003

Polyphor Ltd0 个研究点目标入组 20 人开始时间: 2013年6月10日最近更新: 2013年9月9日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 20

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Male* and female** patients ?18 years of age diagnosed with VAP, i.e., pneumonia that arises more than 96 hours after endotracheal intubation documented or suspected to be due to Pseudomonas aeruginosa requiring treatment with SoC anti-pseudomonas antibiotics.
•2.Patients should have a new or progressive pulmonary infiltrates on the chest radiograph attributable to pulmonary infection.
•any 2 of the following:
•- documented fever, defined as an oral or tympanic temperature greater than or equal to ? 38 degrees Celsius or hypothermia, defined as a core body temperature less than 35 degrees Celsius.
•- an elevated total peripheral white blood cell (WBC) count (WBC greater than 10,000/mm3) or greater than 15% immature neutrophils (bands), regardless of total peripheral WBC count or leukopenia with total WBC greater than 1,000/mm.3
•- new onset of expectorated or suctioned respiratory secretion characterized by purulent appearance indicative of bacterial pneumonia.
•In addition, patients must have Clinical Pulmonary Infection Score of ? 6.
•3.Respiratory specimen taken by endotracheal (ETA) aspirate, suitable for quantitative cultures as well as for performing Gram stain (In addition a rapid diagnosis test will be performed on the baseline ETA from Greece sites, wherever possible).
•4.BAL or mini-BAL sample taken (if there is a medical indication to perform BAL or it is part of the routine protocol in the patient management at the study site for quantitative culture and rapid diagnostic test at baseline).
•5.Venous access available for IV dosing.
•6.Informed consent:
•i.If the patient is unable to comprehend the scope of the trial prior to enrolment due to altered mental status associated with the underlying pneumonia or any other disease: written informed consent to participate in the study must be obtained from the patient?s legally acceptable representative or a relative, as required by national laws, respective regulations and Institutional Review Boards/Independent Ethics Committees/Regional Ethics Boards (IRB/IEC/REB).
•(Written informed consent should be sought from the patient as soon as he/she becomes capable of comprehending the scope of the trial).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

排除标准

•1.Patients with known hypersensitivity to flouroquinolones, carbapenems, cephalosporin, penicillin (beta-lactam antibiotics) or aminoglycoside antibiotics (i.e. all available SoC antibiotics); patients with a clinically significant history of drug allergies and history of anaphylactic reaction and patients with active allergic conditions at the time of screening.
•2.Patients who received more than 24 hours of anti-pseudomonas antibiotic(s) for the current VAP
•3.Female patients who are pregnant or breast feeding;
•4.Known or suspected pulmonary conditions which are likely to interfere with the therapeutic response or might have additional impact on pharmacokinetics (volume of distribution), such as:
•i.evidence of active tuberculosis or other mycobacterium infections,
•ii.cystic fibrosis,
•iii.bronchial obstruction,
•iv.post-obstructive pneumonia due to reasons other than chronic obstructive pulmonary disease (COPD),
•v.known or suspected Pneumocystis jiroveci (Pneumocystis carinii) infection,
•vi.granulomatous disease,
•vii.lung cancer or another malignancy metastatic to the lungs,
•viii.acute respiratory distress syndrome (ARDS) with the underlying cause other than pneumonia,
•ix.empyema.
•5.Patients with Acute Physiology and Chronic Health Evaluation II (APACHE II) score >25.
•6.Presence of septic shock at the time of evaluation for study entry defined as acute occurrence of non-pulmonary organ dysfunctions or acute worsening of chronic non-pulmonary organ dysfunction within the last 48 hours that is not attributable to an alternative process.
•7.History of lung transplant.
•8.Known or suspected Legionella pneumophilia pneumonia; pneumonia caused by Candida spp or Aspergillus spp.
•9.Documented or suspected meningitis, endocarditis, or osteomyelitis.
•10.Patients with impaired renal function [Creatinine Clearance (CrCL) <60 mL/min], patients with increased renal function with CrCL >300 mL/min determined according to Cockroft-Gault formula (Appendix 4).
•11.Patients with significant liver function abnormalities defined as increase in ALT or AST >3 ULN or in bilirubin >2 ULN or other changes in hematology or clinical biochemistry parameters assessed as clinically relevant by the treating physician noted at study baseline.
•12.Patients with known HIV infection with CD4+ cell count < 200/mm3.
•13.Patients with any arrhythmia identified at study baseline or having been diagnosed and/or treated in the last 6 months, which is considered clinically relevant by the treating physician.
•14.Concomitant morbidity of such severity that the patient is likely to die or present with serious medical conditions within 7 days of study entry.
•15.Patients with clinically relevant burns.
•16.Patients who are currently enrolled in, or have not yet completed at least 30 days since ending another investigational device or drug trial or are receiving other investigational agent.

研究者

发起方

Polyphor Ltd

相似试验

进行中（未招募）

1 期

Study conducted in several hospitals to verify the tolerance, safety and efficacy to cure of the study medication (POL7080) and its distribution in the body when given to patients with bronchiectasis caused by bacterium Pseudomonas aeruginosa,requiring intravenous treatment.Acute exacerbation of non-cystic fibrosis bronchiectasis due to Pseudomonas aeruginosa infection.

EUCTR2013-002202-31-DEPolyphor Ltd.20

进行中（未招募）

1 期

Study conducted in several hospitals to check the distribution of study medication(POL7080) in the body, and to verify its safety and its capacity to cure when given in addition to standard treatment for patients with pneumonia caused by bacterium Pseudomonas aeruginosa, following artificial ventilation.

EUCTR2013-001596-21-GRPolyphor Ltd20

进行中（未招募）

1 期

EUCTR2013-002202-31-GBPolyphor Ltd.12

进行中（未招募）

不适用

EUCTR2013-002202-31-ESPolyphor Ltd.20

进行中（未招募）

不适用

A phase II, open-label, multi-centre study to assess the effect of single and multiple oral doses (1 mg, 2 mg, and 3 mg) of everolimus on the pharmacokinetics of tacrolimus in stable renal transplant patients - TEAK Study (Tacrolimus and Everolimus in Allograft Kidney transplantation)

EUCTR2005-001102-31-HUAstellas Pharma GmbH30